DiagnoCure, Hologic deal

DiagnoCure will sell all assets related to the prostate cancer antigen gene 3 (PCA3) biomarker to Hologic’s Gen-Probe Inc. subsidiary. DiagnoCure will receive C$5.5 million ($3.9 million) in cash and repurchase 4.9 million shares of series A convertible preferred shares of DiagnoCure held by Gen-Probe valued at C$1 million ($742,633). ...